Enhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile test

dc.contributor.authorIbrahim, Sherrif F.
dc.contributor.authorKasprzak, Julia M.
dc.contributor.authorHall, Mary A.
dc.contributor.authorFitzgerald, Alison L.
dc.contributor.authorSiegel, Jennifer J.
dc.contributor.authorKurley, Sarah J.
dc.contributor.authorCovington, Kyle R.
dc.contributor.authorGoldberg, Matthew S.
dc.contributor.authorFarberg, Aaron S.
dc.contributor.authorTrotter, Shannon C.
dc.contributor.authorReed, Kenneth
dc.contributor.authorBrodland, David G.
dc.contributor.authorKoyfman, Shlomo A.
dc.contributor.authorSomani, Ally-Khan
dc.contributor.authorArron, Sarah T.
dc.contributor.authorWysong, Ashley
dc.contributor.departmentDermatology, School of Medicineen_US
dc.date.accessioned2023-02-10T18:56:43Z
dc.date.available2023-02-10T18:56:43Z
dc.date.issued2022-03
dc.description.abstractAim: To clinically validate the 40-gene expression profile (40-GEP) test for cutaneous squamous cell carcinoma patients and evaluate coupling the test with individual clinicopathologic risk factor-based assessment methods. Patients & methods: In a 33-site study, primary tumors with known patient outcomes were assessed under clinical testing conditions (n = 420). The 40-GEP results were integrated with clinicopathologic risk factors. Kaplan–Meier and Cox regression analyses were performed for metastasis. Results: The 40-GEP test demonstrated significant prognostic value. Risk classification was improved via integration of 40-GEP results with clinicopathologic risk factor-based assessment, with metastasis rates near the general cutaneous squamous cell carcinoma population for Class 1 and ≥50% for Class 2B. Conclusion: Combining molecular profiling with clinicopathologic risk factor assessment enhances stratification of cutaneous squamous cell carcinoma patients and may inform decision-making for risk-appropriate management strategies.en_US
dc.eprint.versionFinal published versionen_US
dc.identifier.citationIbrahim, S. F., Kasprzak, J. M., Hall, M. A., Fitzgerald, A. L., Siegel, J. J., Kurley, S. J., Covington, K. R., Goldberg, M. S., Farberg, A. S., Trotter, S. C., Reed, K., Brodland, D. G., Koyfman, S. A., Somani, A.-K., Arron, S. T., & Wysong, A. (2022). Enhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile test. Future Oncology (London, England), 18(7), 833–847. https://doi.org/10.2217/fon-2021-1277en_US
dc.identifier.urihttps://hdl.handle.net/1805/31219
dc.language.isoenen_US
dc.publisherFuture Medicineen_US
dc.relation.isversionof10.2217/fon-2021-1277en_US
dc.relation.journalFuture Oncologyen_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0*
dc.sourcePublisheren_US
dc.subjectclinicopathologic risk factorsen_US
dc.subjectcutaneous squamous cell carcinomaen_US
dc.subjectgene expression profileen_US
dc.titleEnhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile testen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Ibrahim2021Enhanced-CCBYNCND.pdf
Size:
1.88 MB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: